WM-1119

WM-1119 is a potent, selective, and orally bioavailable small molecule inhibitor of the MYST family lysine acetyltransferases KAT6A (MOZ) and KAT6B (MORF). It functions as a reversible competitor of acetyl coenzyme A (Ac-CoA), binding to the Ac-CoA binding site to inhibit histone acetylation. Preclinical studies have shown that WM-1119 induces cellular senescence and cell cycle arrest at the G1/S restriction point, particularly in INK4A/ARF-dependent pathways, without causing DNA damage. It has demonstrated significant anti-tumor activity in models of acute myeloid leukemia (AML), lymphoma, and hepatocellular carcinoma. Additionally, WM-1119 has been explored for its ability to suppress IgE-mediated mast cell activation and allergic inflammation by reducing AP-1 signaling and histone acetylation at the Fos promoter.